Yousif Capital Management LLC Sells 454 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Yousif Capital Management LLC reduced its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 2.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,605 shares of the company’s stock after selling 454 shares during the period. Yousif Capital Management LLC’s holdings in Pacira BioSciences were worth $437,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PCRX. Sterling Capital Management LLC lifted its stake in Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after acquiring an additional 1,208 shares in the last quarter. Ancora Advisors LLC bought a new position in Pacira BioSciences during the 4th quarter valued at $26,000. PNC Financial Services Group Inc. lifted its stake in Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after acquiring an additional 513 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Pacira BioSciences during the 4th quarter valued at $103,000. Finally, State of Wyoming lifted its stake in Pacira BioSciences by 8.0% during the 4th quarter. State of Wyoming now owns 6,566 shares of the company’s stock valued at $124,000 after acquiring an additional 487 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. HC Wainwright raised their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a research note on Tuesday, April 8th. Barclays raised their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Needham & Company LLC decreased their target price on Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Finally, Wall Street Zen raised Pacira BioSciences from a “hold” rating to a “buy” rating in a research report on Friday, June 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $26.44.

Pacira BioSciences Trading Up 0.3%

Shares of Pacira BioSciences stock opened at $24.23 on Friday. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $29.61. The firm has a market cap of $1.12 billion, a PE ratio of -10.63 and a beta of 0.52. The stock has a fifty day moving average price of $25.47 and a 200-day moving average price of $23.83. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.41 and a quick ratio of 1.99.

Insider Buying and Selling

In other Pacira BioSciences news, SVP Lauren Riker sold 5,578 shares of the firm’s stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total value of $146,199.38. Following the completion of the transaction, the senior vice president now owns 59,564 shares in the company, valued at $1,561,172.44. This trade represents a 8.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.40% of the stock is currently owned by insiders.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.